Geovax Labs Inc (nasdaq:GOVX) Share Price

Company Profile

Business description
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company’s key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Contact
1900 Lake Park Drive
Suite 380
SmyrnaGA30080
USA
T: +1 678 384-7220
E: [email protected]
https://www.geovax.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17

Recommended

As investors toil in complexity the obvious solution may be the right one.

Mark LaMonica, CFA | 24 July 2025

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.

Matthew Dolgin, CFA | 23 July 2025

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

John Abernethy | 23 July 2025

Index	Last price	Change	% Change
All Ordinaries	8,934.30	45.10	-0.50%
CAC 40	7,834.58	16.30	0.21%
DAX 40	24,217.50	78.43	-0.32%
Dow JONES (US)	44,901.92	208.01	0.47%
FTSE 100	9,120.31	18.06	-0.20%
HKSE	25,388.35	278.83	-1.09%
NASDAQ	21,108.32	50.36	0.24%
Nikkei 225	41,456.23	370.11	-0.88%
NZX 50 Index	12,853.46	48.33	0.38%
S&P 500	6,388.64	25.29	0.40%
S&P/ASX 200	8,666.90	42.50	-0.49%
SSE Composite Index	3,593.66	12.07	-0.33%